SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Terremoto Biosciences, a biotechnology company developing highly targeted, small molecule medicines, today announced the closing of a $175 million Series B financing round. The round includes new investors EcoR1 Capital, Novo Holdings and Cormorant Capital, among others, and participation from existing investors OrbiMed and Third Rock…
Click here to view original post
Copyright © 2023 Biotech Networks, LLC
